Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece.

Gourzoulidis GeorgeArgyro SolakidiMarina PsarraEleni NikitopoulouCharalampos Tzanetakos

Published in: Clinical drug investigation (2023)

Tofacitinib was estimated to be a cost-effective option for the treatment of active ankylosing spondylitis in Greece for both biologic-naive and biologic-experienced patients.

Keyphrases

ankylosing spondylitis
rheumatoid arthritis
disease activity
end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
combination therapy
replacement therapy
antiretroviral therapy